AHA to Sanofi U.S./Sanofi Genzyme Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs

AHA to Sanofi U.S./Sanofi Genzyme Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs to Hospitals and Health Systems

AHA expresses profound concern about actions Sanofi U.S./Sanofi Genzyme are taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.

Key Resources

Related Resources

Advancing Health Podcast
Health Equity at the Center of Rural Care
Public
Case Studies
UK St. Claire | Kentucky
Public
AHA Center for Health Innovation Market Scan
Assessing the Health Care Environment for 2025
Public
AHA Center for Health Innovation Market Scan
Register Now for the AHA Rural Health Care Leadership Conference
Public
Fact Sheets
Fact Sheet: Hospitals & Health Systems and Artificial Intelligence
Member
Letter/Comment
AHA Comments on CMS Proposed Medicare Drug Pricing Model
Public